Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 Operating Margin % is 8.12% as of Mar. 2026, which is 65% above its 10-year median of 4.93. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 958 Drug Manufacturers companies, Vilin Bio Med ranks better than 51.25% on this metric.
Vilin Bio Med Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Vilin Bio Med's Operating Margin % or its related term are showing as below:
NSE:VILINBIO'
s Operating Margin % Range Over the Past 10 Years
Min: 3.49 Med: 4.93 Max: 20.42
Current: 8.12
NSE:VILINBIO's Operating Margin % is ranked better than 51.25% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.34
vs NSE:VILINBIO: 8.12
Vilin Bio Med's 5-Year Average Operating Margin % Growth Rate was 2.00% per year.
Vilin Bio Med (NSE:VILINBIO) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Vilin Bio Med Operating Margin % Related Terms
Vilin Bio Med Operating Margin % Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VILINBIO vs ZTS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Vilin Bio Med's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vilin Bio Med (NSE:VILINBIO) has a Operating Margin % of 8.12% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Vilin Bio Med and its competitors. This is 65% above median its historical median of 4.93. Over the past decade, Vilin Bio Med's Operating Margin % has ranged from 3.49 to 20.42. According to the industry distribution chart, Vilin Bio Med ranks #467 out of 958 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Vilin Bio Med's Operating Margin % too high?
Vilin Bio Med's current Operating Margin % of 8.12% is 65% above median its 10-year median of 4.93. Over the past 10 years, this metric has ranged from a low of 3.49 to a high of 20.42. The Drug Manufacturers industry median Operating Margin % is 7.34. Vilin Bio Med's value of 8.12% is 10.6% above this industry median. Based on the distribution chart, Vilin Bio Med ranks #467 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #467 out of 958 companies for Operating Margin %. This puts Vilin Bio Med in the upper half of its industry. The industry median Operating Margin % is 7.34. Vilin Bio Med's value of 8.12% is 10.6% above this benchmark. Historically, Vilin Bio Med's own Operating Margin % has ranged from 3.49 to 20.42 over the past decade. While the company's 10-year median is 4.93 vs. the industry median of 7.34, Vilin Bio Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.34, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current Operating Margin % of 8.12% is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current Operating Margin % is 8.12%, which is 65% above median its own 10-year median of 4.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current Operating Margin % is 8.12%, which is 65% above median its 10-year median of 4.93 and 10.6% above the Drug Manufacturers industry median of 7.34. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current Operating Margin % is 8.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
Operating Margin %: 8.12% (65% above median its 10-year median of 4.93)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 10.6% above the Drug Manufacturers median (#467 of 958)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
